"New data from our diverse portfolio, spanning multiple platforms and combinations, reinforce our pursuit of the next wave of hematology advances across a spectrum of blood diseases with the highest unmet needs." Key data being presented by Bristol Myers Squibb and its partners at the 2023 ASH Annual Meeting and Exposition include: Cell Therapy Targeted Protein Degradation Additional Novel Treatment Modalities You can find additional information about BMS' presence at the meeting on the ASH website. Selected Bristol Myers Squibb studies at the 65 th ASH Annual Meeting and Exposition include: Contacts Bristol Myers Squibb: Media Inquiries: Investors: Read full story here